Menu Search
Equities

Sectra AB

SECT B:STO

Sectra AB

Actions
Health CareMedical Equipment and Services
  • Price (SEK)270.40
  • Today's Change-1.85 / -0.68%
  • Shares traded19.06k
  • 1 Year change+92.78%
  • Beta1.2147
Data delayed at least 15 minutes, as of Nov 22 2024 09:51 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Sectra AB grew revenues 26.84% from 1.36bn to 1.72bn while net income improved 14.25% from 374.96m to 428.39m.
Gross margin47.01%
Net profit margin24.71%
Operating margin30.29%
Return on assets15.16%
Return on equity29.42%
Return on investment28.08%
More ▼

Cash flow in SEKView more

In 2024, Sectra AB did not generate a significant amount of cash. However, the company earned 326.33m from its operations for a Cash Flow Margin of 18.92%. In addition the company used 130.74m on investing activities and also paid 222.20m in financing cash flows.
Cash flow per share2.83
Price/Cash flow per share90.11
Book value per share8.55
Tangible book value per share7.19
More ▼

Balance sheet in SEKView more

Sectra AB uses little debt in its capital structure as supported by a debt to capital ratio of 2.70%.
Current ratio1.69
Quick ratio--
Total debt/total equity0.0277
Total debt/total capital0.027
More ▼

Growth rates in SEK

Year on year, growth in earnings per share excluding extraordinary items increased 14.25%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)16.57
EPS (TTM) vs
TTM 1 year ago		16.96
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.